#South Korea #Seoul #PCR Testing #Seegene #CURECA

Seegene's CURECA™: The Future of PCR Testing Automation

In a bold move that could redefine the landscape of molecular diagnostics, Seegene Inc. introduced its innovative CURECA™ system at the recent ESCMID Global 2025 conference held in Vienna. This cutting-edge solution is engineered to fully automate the PCR (Polymerase Chain Reaction) testing process, enabling laboratories to enhance efficiency and accuracy in diagnostics.

The unveiling of CURECA™ was marked by a conceptual video that captivated the attention of over 2300 healthcare professionals, including leading figures from Europe and beyond. This system is poised to address the inherent challenges of manual PCR testing, such as human error and labor-intensive procedures, paving the way for a new era of streamlined and reliable testing.

Key Features of CURECA™

CURECA™ boasts a modular design that accommodates diverse testing needs, supporting the processing of various sample types such as stool, urine, blood, and sputum. The system automates the entire workflow from sample preparation to PCR amplification and result analysis, which experts in the field deem as a revolutionary shift in the molecular diagnostics paradigm.

Dr. YoungSeag Baeg, Seegene’s head of Strategy and Planning, stated that this system is designed to integrate seamlessly into existing laboratory workflows, significantly reducing turnaround times and resource constraints. Attendees at the conference echoed this sentiment, expressing optimism about the potential impacts of CURECA™ on laboratory operations, especially for the diagnosis of infectious diseases.

Industry Reception and Anticipated Impact

Participants from various backgrounds praised CURECA™ for its ability to eliminate the human factor in critical testing processes. One expert noted, "CURECA™ not only mitigates the risks associated with manual processing but also promises consistent and time-efficient test results. This level of automation is unprecedented in the current market."

Many lab professionals highlighted the pain points associated with sample handling and the labor-intensive nature of pre-analytical procedures. One participant stated, "A system that can automate these steps has the potential to change how we conduct tests. The implications for patient care and laboratory efficiency are enormous."

Seegene aims to make CURECA™ accessible not just to large healthcare facilities but also to smaller labs, ensuring that improved diagnostic capabilities can benefit a broader range of healthcare providers.

Modular and Customizable

The modular structure of CURECA™ includes a customizable Pre-processing System (CPS) designed for optimizing sample preparation tasks. The SPS (Sample Pre-processing System) allows for the automation of tube loading and sample handling, enabling labs to manage complex workflows with a high degree of efficiency.

Furthermore, CURECA™ encompasses a modular architecture that supports various diagnostic needs by integrating systems like ALIQ (aliquoting primary samples) and CEFA (comprehensive automation), ensuring flexibility in meeting the demands of different laboratory environments.

This adaptability is vital as it allows laboratories to configure their setups based on specific spatial and operational requirements, thereby maximizing space utilization and improving workflow efficiency.

Looking to the Future

With a strong positive response from the ESCMID conference, Seegene is poised to leverage the interest surrounding CURECA™ as they continue to refine and develop the technology. CEO Jong-Yoon Chun remarked, “The overwhelming enthusiasm for our CURECA™ concept demonstrates a clear demand for next-generation diagnostic solutions that can cater to the evolving needs of healthcare worldwide.”

As Seegene prepares for the official launch and further demonstrations at upcoming events, the healthcare community eagerly anticipates the transformative impact that CURECA™ will bring to molecular diagnostics, emphasizing a future where accurate and efficient testing is accessible to all.

By addressing both the technological and human aspects of PCR testing, CURECA™ is expected to lead the way towards establishing laboratory automation as a standard practice in diagnostics, ultimately providing better healthcare outcomes around the globe.

For more information about CURECA™ and Seegene's initiatives, visit Seegene's official website.